The estimated Net Worth of John R Leone is at least $22.8 Tausend dollars as of 22 May 2020. Mr. Leone owns over 2,069 units of Windtree Therapeutics stock worth over $22,793 and over the last 20 years he sold WINT stock worth over $0. In addition, he makes $0 as Independent Director at Windtree Therapeutics.
Sign up
Mr. Leone WINT stock SEC Form 4 insiders trading
John has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,069 units of WINT stock worth $15,000 on 22 May 2020.
The largest trade he's ever made was buying 2,069 units of Windtree Therapeutics stock on 22 May 2020 worth over $15,000. On average, John trades about 259 units every 0 days since 2004. As of 22 May 2020 he still owns at least 7,473 units of Windtree Therapeutics stock.
You can see the complete history of Mr. Leone stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Leone biography
John R. Leone serves as Independent Director of the Company. He currently serves as Chairman of the Board’s nominating and governance committee and as a member of the audit committee. Mr. Leone has over 30 years of experience in pharmaceutical operations, commercial portfolio management, and financing life science companies. His commercial experience includes significant domestic and international executive management roles and direct responsibility for the commercial launch of numerous pharmaceutical products. Since January 2017, Mr. Leone has served as an Operating Partner at Madryn Asset Management, an investment platform focused on providing capital to healthcare companies. Madryn Asset Management was spun out from Visium Asset Management, or Visium, where Mr. Leone was a Partner from May 2013 to January 2017. Prior to joining Visium, Mr. Leone was a Partner from 2007 to 2013 at Paul Capital Healthcare, a private equity firm that manages one of the largest dedicated healthcare funds globally. Previously, Mr. Leone served as President and Chief Executive Officer at Cambrex Corporation, and as Senior Vice President and Chief Operating Officer of U.S. Commercial Operations at Aventis Pharmaceuticals, or Aventis. While at Aventis, he played a key role in spearheading the successful integration of its predecessor companies, Rhone-Poulenc Rorer and Hoechst Marion Roussel, and had responsibility for all commercial business units, including oncology, metabolism, cardiovascular, dermatology, respiratory and anti-infective. Mr. Leone served on the Board of Pernix Therapeutics Holdings, Inc. from November 2017 until 2019 and served on the Board of ViroPharma Incorporated from January 2006 until its acquisition in March 2014. Mr. Leone received his B.S. degree in Engineering from the U.S. Military Academy at West Point and his M.B.A. from the University of Colorado.
How old is John Leone?
John Leone is 72, he's been the Independent Director of Windtree Therapeutics since 2018. There are 1 older and 15 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
What's John Leone's mailing address?
John's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Insiders trading at Windtree Therapeutics
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... und Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
What does Windtree Therapeutics do?
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
What does Windtree Therapeutics's logo look like?
Complete history of Mr. Leone stock trades at Windtree Therapeutics
Windtree Therapeutics executives and stock owners
Windtree Therapeutics executives and other stock owners filed with the SEC include:
-
Craig Fraser,
President, Chief Executive Officer, Director -
Craig E. Fraser,
Pres, CEO & Director -
Steven Simonson,
Senior Vice President and Chief Medical Officer -
Eric L. Curtis M.B.A.,
Sr. VP & COO -
John P. Hamill,
Sr. VP, CFO & Corp. Sec. -
Mary Templeton,
Senior Vice President, General Counsel and Corporate Secretary -
James Huang,
Independent Chairman of the Board -
Brian Schreiber,
Independent Director -
Bruce Peacock,
Independent Director -
Joseph Mahady,
Independent Director -
John Leone,
Independent Director -
Daniel Geffken,
Independent Director -
Pratap Paruchuru,
Executive Director of Clinical Development -
Eric Curtis,
Chief Operating Officer, Senior Vice President -
John Hamill,
Chief Financial Officer, Senior Vice President -
Dr. Steven G. Simonson,
Sr. VP & Chief Medical Officer -
Diane Carman Esq.,
Sr. VP & Gen. Counsel -
Dr. Ronald L. Dundore,
Exec. Director of Regulatory Affairs & Quality -
Tracy Rarick,
Head of Operations & Program Management -
George Cox,
VP of Technical Operations -
Diane Carman,
SVP & General Counsel -
Leslie J. Williams,
Director -
Evan Loh,
Director -
Ii Investments Ltd Lph,
10% owner -
Pharmaceutical Holdings Ltd...,
10% owner -
John A Tattory,
SVP & CFO -
Mark Strobeck,
Director -
Capital Inc. Bioengine,
10% owner -
Laboratories, Inc. Center,
10% owner -
Robert A Scott,
Director